COPD Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to give their informed consent and take part in the study
• People aged between 35 and 80 years old at the time of signing the consent form
• People who have emphysema (either evenly spread or unevenly spread across the lungs) confirmed on a CT scan taken within the last 6 months
• People whose CT scan shows that at least 50% of the target lung lobe is destroyed
• People who have stopped smoking for at least 3 months
• People who experience significant breathlessness, scoring 2 or above on a standard breathlessness scale called the mMRC questionnaire
• People whose breathing test results (after using a bronchodilator inhaler) fall within a specific range, showing moderately to severely reduced lung function (confirm with trial site for exact values)
• People whose lung volume measurements (after using a bronchodilator inhaler) show that the lungs are significantly overinflated (confirm with trial site for exact values)
• People who can walk at least 100 metres during a 6-minute walk test
• People who are members of, or covered by, a French social security scheme

Who may not be able to join:

• People whose main diagnosis is asthma
• People who have had more than 3 flare-ups of their lung condition in the past year, or 2 or more that required a hospital stay
• People who have had a heart attack or stroke in the 6 months before joining the trial
• People who have had symptoms of heart failure in the 6 months before joining the trial
• People whose chest CT scan shows certain abnormalities, such as a very large air pocket in the lung, a certain type of emphysema around the edges of the lung, a lung nodule larger than 0.8cm (unless it has been known and stable for more than a year), scarring of lung tissue, or abnormally widened airways
• People whose lung blood flow scan shows that the lobe with the poorest blood flow is not the same lobe that has the most emphysema damage
• People with evenly spread emphysema whose blood flow scan shows less than a 10% difference in blood flow between the lung being treated and the lobe being targeted
• People whose blood oxygen level is very low or whose carbon dioxide level is very high, as measured by an arterial blood test
• People whose heart ultrasound shows that the heart is not pumping effectively, or that the blood pressure in the lung arteries is too high
• People who have previously had a lung removed, or have had lung surgery on the same side as the lobe being targeted in this trial
• People who have previously had a collapsed lung (pneumothorax) on the same side as the lobe being targeted
• People who have previously had an endoscopic lung volume reduction procedure
• People who have been taking oral steroid tablets at a dose above 20mg per day within the 4 weeks before joining the trial
• People with significant airway widening causing symptoms, or with certain bacterial or fungal infections in the airways
• People with cancer that has spread to other parts of the body and who are currently being treated, or whose treatment ended less than 5 years ago
• People who are pregnant or breastfeeding
• People with a nickel allergy
• People who are under legal guardianship or a court-appointed protection order
• People who are currently taking part in another interventional clinical trial
• People who have any other condition that, in the opinion of the trial doctor, could interfere with the study or affect their ability to participate fully — for example, untreated alcohol dependence, substance use, or difficulty attending regular follow-up appointments
• People whose test results using a device called the Chartis system show that air is able to move between lung sections in a way that would affect the procedure (this is checked during the study process)

Important: Always verify eligibility with the trial site directly before applying.